Loading...

BBIO BRIDGEBIO PHARMA INC Product Launches 8-K Filing

BRDG

BB

BRIDGEBIO PHARMA INC

(BBIO)

2023 8-K

Show Summary

Show Summary

Financial Statements

Management Changes

Financial Results

Financial Update

Q3 Financial Results

Gene Therapy Results

Joint Venture Formation

Financial Results

Appointment of President an...

Annual Meeting of Stockholders

Phase 2 Results Announcement

Financial Results

Underwriting Agreement for ...

License Agreement with Bayer

Financial Results

Funding Agreement for acora...

Presentation Update

Earnings Reports

Private Placement

Financial Results

Phase 3 Clinical Trial Results

Annual Meeting of Stockholders

Equity Distribution Agreement

Financial Results

Underwriting Agreement for ...

Positive Phase 2 results fo...

Financial Results and Manag...

External Links:

BridgeBio Pharma announced positive results from its Phase 2 clinical trial of infigratinib in children with achondroplasia, with a mean change in annualized height velocity of +3.03 cm/yr at six months in the highest dose level (Cohort 5).

AI Assistant

BRIDGEBIO PHARMA INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.